FDA pushes to remove pregnancy drug, company pushes back

  • 📰 wjxt4
  • ⏱ Reading Time:
  • 68 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 30%
  • Publisher: 63%

Business News News

Business Business Latest News,Business Business Headlines

The maker of the only U.S. drug intended to prevent premature births is making a last-ditch effort this week to keep its medication on the market, even as health regulators insist that it doesn't work.

This image provided by Covis Pharma shows packaging for the company's Makena medication. Covis, the maker of the only U.S. drug intended to prevent premature births will make a last-ditch effort to keep its medication on the market in October 2022, even as health regulators revisit mounting evidence that it doesn't work. – The maker of the only U.S.

About 10% of U.S. births come too early — before 37 weeks, raising the risk of serious health problems and even death in infants. Complicating the Makena debate is support from the leading U.S. obstetrics group to keep the decade-old drug available while more research is done. “Based on the evidence shown today, Makena is not shown to be effective,” said FDA’s drug chief, Dr. Patrizia Cavazzoni, in opening remarks Monday. “Its benefit and risk profile is unfavorable and it should be withdrawn from the market.”, which allows drugs like Makena to launch based on promising early results while additional, usually larger, studies are conducted.

In recent years, the FDA's cancer division has begun prodding companies to stop selling their drugs for uses granted under these so-calledThe FDA approved Makena in 2011 based on a small study suggesting it reduced rates of premature birth in women with a history of early deliveries. Makena consists of a synthetic version of the hormone progesterone, which helps the uterus grow and maintain a pregnancy. Women can start the shots after 16 weeks of pregnancy.

In briefing documents released this month, the FDA said leaving Makena on the market “incurs false hopes, the risks associated with treatment, and other burdens” like excess medical spending. According to a recent

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 246. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA pushes to remove pregnancy drug, company pushes backThe maker of a drug intended to reduce premature births is making a last-ditch effort to keep its medication on the market, even as health regulators insist that it doesn’t work
Source: WOKVNews - 🏆 247. / 63 Read more »

FDA pushes to remove pregnancy drug, company pushes backThe maker of a drug intended to reduce premature births is making a last-ditch effort to keep its medication on the market, even as health regulators insist that it doesn’t work.
Source: WTVYNews4 - 🏆 590. / 51 Read more »

FDA pushes to remove pregnancy drug, company pushes backThe maker of a drug intended to reduce premature births is making a last-ditch effort to keep its medication on the market, even as health regulators insist that it doesn’t work. fda pregnancy kprc2 click2houston
Source: KPRC2 - 🏆 80. / 68 Read more »

Company pushes back against FDA efforts to remove pregnancy drugA Food and Drug Administration meeting that opened Monday comes more than two years after the agency declared the drug Makena ineffective and called for its removal.
Source: News4SA - 🏆 251. / 63 Read more »